{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T22:55:12Z","timestamp":1692572112774},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.genhosppsych.2010.10.009","type":"journal-article","created":{"date-parts":[[2010,12,24]],"date-time":"2010-12-24T09:19:37Z","timestamp":1293182377000},"page":"84.e5-84.e7","source":"Crossref","is-referenced-by-count":3,"title":["Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome"],"prefix":"10.1016","volume":"33","author":[{"given":"Pang-Yen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Chuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.encep.2007.11.007","article-title":"Neuroleptic malignant syndrome and atypical antipsychotics: A brief review","volume":"34","author":"Khaldi","year":"2008","journal-title":"Encephale"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1345\/aph.1E492","article-title":"Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient","volume":"39","author":"Aruna","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pnpbp.2004.10.001","article-title":"Neuroleptic malignant syndrome and clozapine withdrawal at the same time?","volume":"29","author":"Margetic","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1440-1819.2008.01894.x","article-title":"Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia","volume":"63","author":"Srivastava","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0025","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/schbul\/sbm033","article-title":"Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone","volume":"33","author":"Olfson","year":"2007","journal-title":"Schizophr Bull"},{"issue":"Suppl 12","key":"10.1016\/j.genhosppsych.2010.10.009_bb0030","first-page":"5","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/j.1440-1665.2006.02273.x","article-title":"Trends in antipsychotic prescribing in schizophrenia in Auckland","volume":"14","author":"Wheeler","year":"2006","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0045","first-page":"99","article-title":"Neuroleptic malignant syndrome due to depot fluphenazine","volume":"40","author":"Grunhaus","year":"1979","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0010-440X(99)90071-8","article-title":"The neuroleptic malignant syndrome: an Indian experience","volume":"40","author":"Chopra","year":"1999","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0055","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/01.jcp.0000096253.95165.e8","article-title":"Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome","volume":"23","author":"Tofler","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/PCC.v09n0311f","article-title":"Risperidone-induced neuroleptic malignant syndrome in neurodegenerative disease: a case report","volume":"9","author":"Johnson","year":"2007","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003495-200363050-00004","article-title":"Intramuscular preparations of antipsychotics: uses and relevance in clinical practice","volume":"63","author":"Altamura","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.genhosppsych.2010.10.009_bb0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome. A case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch Gen Psychiatry"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834310002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834310002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T03:28:12Z","timestamp":1544066892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834310002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0163834310002057"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2010.10.009","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}